Oxipit enters agreement to be acquired by Sectra to scale autonomous AI in radiology

Oxipit, a developer of clinically validated AI solutions for radiology, announced that Sectra (STO: SECT B) has signed an agreement to acquire the company.

VILNIUS, LITHUANIA, March 5, 2026 /EINPresswire.com/ -- Oxipit, a developer of clinically validated AI solutions for radiology, today announced that Sectra (STO: SECT B) has entered into an agreement to acquire Oxipit, UAB. The transaction is subject to customary closing conditions and is expected to be completed during March 2026.

Founded in 2017, Oxipit develops CE-marked AI solutions for radiology, including ChestLink—the world’s first CE Class IIb certified autonomous AI solution for chest X-ray analysis. ChestLink automatically identifies high-confidence normal examinations and removes them from the radiologist’s worklist, enabling specialists to focus on cases that require their clinical judgment. The company has recently expanded its portfolio into CT and musculoskeletal imaging.

Both companies take a customer-first approach to AI in healthcare: technology should integrate seamlessly into existing clinical workflows, delivering measurable benefit without adding complexity or requiring radiologists to adopt new platforms. Sectra’s global reach and established relationships with healthcare providers create a clear path to scaling Oxipit’s validated technology to more markets.

“This is an important step in Oxipit’s journey,” says Peter Corscadden, CEO of Oxipit. “Sectra’s global footprint, strong clinical partnerships, and deep integration into radiology workflows create a powerful platform to responsibly scale autonomous AI. Together, we can accelerate access to AI solutions that fit naturally into daily reporting practice.”

He adds:

"As a pioneer in autonomous radiology AI, Oxipit has shown that AI can deliver immense value beyond traditional CAD. By joining forces with Sectra—a leader in workflow integration and customer care—we are moving from a team of greats to a great team.”

Oxipit will continue to operate through completion of the transaction and existing customers and partners can expect full continuity of service, support, and development.



About Oxipit

Founded in 2017 by experts in medicine and data science, Oxipit is a leader in AI-based medical imaging. The company introduced ChestEye in 2019 for detection of 75 chest X-ray findings and launched ChestLink in 2022 as the world’s first CE Class IIb certified solution capable of identifying normal chest X-rays with 99.9% sensitivity. In 2026, Oxipit expanded its portfolio into chest CT and musculoskeletal X-ray imaging, continuing to support radiologists through workflow-integrated detection, prioritisation, and reporting support in daily clinical practice worldwide. Read more at www.oxipit.ai

About Sectra
Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2024/2025 fiscal year totaled SEK 3,240 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.

Milda Shams
Oxipit
email us here
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.